Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
I am resigning myself to the fact my patience is going to be severely tested with this share but no matter how frustrated I get I still have no intention on selling up as I have to stand firm in my belief in this company. Time and time again I see investors become transfixed with their share and seem to be wearing blinkers, failing to see the downside or reality of how their chosen share is going no-where. I've had to ask myself, am I doing that with Novacyt ? So I do play devil's advocate with it, I look at it in the coldest unobstructed view possible and without fail I come back to the same result, Novacyt is on the road to huge success. Buffets " In the short run the stock market is a voting machine, yet in the long run it is a weighing machine " has never applied so suitably to a company as it does to Novacyt.
I only have a few shares in this (wish it was more) as my main holdings are in Novacyt, been there since Jan/Feb. This is the first company that has gained my interest since I had my gut feeling about Novacyt. I love the technology and the man behind it, he comes across as a committed decent guy. I watched the shenanigans with TB etc and I think it's safe to say my feelings on it and him are probably best not printed. Just want to wish you all the best of luck and I will be keeping my fingers crossed for this company, I had to learn alot of patience in Nova but if you believe in the company and the people behind it stick with your gut feeling and wait..........GLA
I don't think many will forget Americas " modern day piracy " when they intercepted millions of pounds worth of PPE en route to France and Germany back in April. That's what you're up against.
I must be one of the few who isn't that concerned about vaccines, there is no vaccine that is going to get rid of testing and further diagnostics for many years yet, it's just not possible and anyone who believes otherwise mustn't be fully taking on board the scale of a pandemic. Before covid ThermoFisher was happy to pay Qiagen over 10 billion, that was without a hint of a pandemic and once covid arrived there obviously wasn't a price high enough for Qiagen to accept even when they were left with a 95 million pound bill for withdrawal of the sale. The money involved in diagnostics was staggering, is staggering and will continue to be staggering. Novacyt has this huge pile of cash, no debts and a proven in demand asset, they will get there it's just a matter of when and it won't be tomorrow but nor will it be too far away.
Tay as always is absolutely correct, diagnostics within the NHS is changing on an unprecedented level, the labs are being taken to the wards and not just for covid - for everything. None of us can quite imagine the scale of what is happening here.
Great to have this chat back up and some of you will never know how appreciative I am to have access to your research and even support thank you for sharing it there's a great camaraderie on this forum. I still think it's important to keep at the forefront the knowledge that Novacyt is not just a covid stock but a truly successful diagnostics company . As a business it has been really put to the test, on expertise, management, logistics, scale and results and has definitely succeeded it's hurdles. Going forward they have what any business can only dream off - an opening, their feet are firmly in the door. This time last year who would have taken their calls let alone sit down to discuss deals, now they have the most crucial element of all, the contacts and have proven themselves to deliver. This really is just the start for Novacyt the world of diagnostics, tests, equipment reaches far past covid and I have absolutely every faith they are going to grow into something completely unrecognisable from today.
And I believe she is a woman ?? Not that it really matters I guess. I'm not surprised to hear Novacyt unlike all other covid stock didn't make any comment about Monday, I think they, probably rightly, see themselves not as a covid stock but a serious diagnostics company.
I have been here since the very start and his chat has been invaluable, so many of you have provided so much information and reassurance along the way. I remember those long months sitting around 2,50 and not a word (bit like now!) from Lord Mullis himself. Monday was crazy and I have my own theories about that ! It was definitely an attack and of course not being able to come on here made it worse. When I'm at my most worried I go to Tay on twitter, she is amazing and I read her comments for reassurance, thank you Tay ! Hopefully can read all your comments later on, it's not the same without all of you especially when under attack ;) Good luck everyone and again thank you to all those who provide such good research
Think Novacyt will be busy for a very long time if this is anything to go by. New strain of virus less vulnerable to antibodies and hence probably vaccines will be less effective! Humans to mink and back to humans... There are so many twists and turns still ahead for all mankind...
https://www.cnbc.com/2020/11/04/denmark-to-cull-entire-mink-population-after-coronavirus-mutation-spreads-to-humans.html
This is quite amazing, been here from the beginning and I still remember days, even weeks, where I wanted to grab hold of Graham Mullis and shake him for some news the silence seemed never ending, but I kept the hope everything said this was a 5 star company . Patience Patience Patience........
As per Novacyt's RNS of 28th January 2020, the full year results will be published by end of April (see excerpt from RNS below). Just a few days left now. This could hopefully also provide the long anticipated opportunity to update on the detailed numbers, sales, plans, partnerships and progress so far this year. Based on what has been revealed by Novacyt themselves so far, IMO this promises to be an epic update... not long now! IMO DYOR
##############
Tue, 28th Jan 2020 07:00
RNS Number : 0756B
Novacyt S.A.
28 January 2020
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
FULL YEAR TRADING AND OPERATIONAL UPDATE
Paris, France and Camberley, UK - 28 January 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020.
Former head of PHE on Newsnight, absolutely livid with government response so far, including lack of testing...
https://www.msn.com/en-gb/news/uknews/weve-wasted-a-month-former-public-health-chief-issues-furious-condemnation-of-uk-coronavirus-response/ar-BB115gJb?ocid=spartanntp&pfr=1
US admit testing shortages...
https://www.bbc.co.uk/news/world-us-canada-51761435